ZURICH (Reuters) – Lonza Group said on Monday that China’s Junshi Biosciences is using the Swiss contract drug manufacturer’s technology to help produce a neutralizing antibody against COVID-19.
Lonza said Junshi’s first neutralizing antibody against the new coronavirus was expressed using the Swiss company’s GS Xceed gene expression system and has entered into clinical trials in China, in which the first healthy volunteer was dosed in June in an early-stage safety study.
(Reporting by John Miller)
